Evidence map›Paper›PMID 34614221›Full record

ArticleAllergy2022

Allergic eye disease: Blocking LTB4/C5 in vivo suppressed disease and Th2 & Th9 cells.

Malihe Eskandarpour, Xiaozhe Zhang, Alessandra Micera, Sarah Zaher, Frank D P Larkin, Miles Nunn, Stefano Bonini, Wynne Weston-Davies, Virginia L Calder

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Allergy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Malihe EskandarpourOcular Immunology Group, UCL Institute of Ophthalmology, London, UK.ORCID 0000-0002-6380-5389
Xiaozhe ZhangOcular Immunology Group, UCL Institute of Ophthalmology, London, UK.
Alessandra MiceraUOSD Research Laboratories, IRCCS-fondazione Bietti, University Campus Bio-Medico, Rome, Italy.
Sarah ZaherNIHR Moorfields Clinical Research Facility, Moorfields Eye Hospital, London, UK.
Frank D P LarkinNIHR Moorfields Clinical Research Facility, Moorfields Eye Hospital, London, UK.
Miles NunnAkari Therapeutics plc, London, UK.
Stefano BoniniOphthalmology Operative Complex Unit, University Campus Bio-Medico, Rome, Italy.
Wynne Weston-DaviesAkari Therapeutics plc, London, UK.
Virginia L CalderOcular Immunology Group, UCL Institute of Ophthalmology, London, UK.ORCID 0000-0003-1422-2926

Funding

Department of Health
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Eye DiseasesHypersensitivityHumansLeukotriene B4Th2 CellsT-Lymphocytes, Helper-InducerLeukotriene B4

Identifiers

PMID34614221
PMCPMC9292376

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.